Core C - The Administrative Core will serve to coordinate administrative interactions between the different projects, their leadership, and scientists within the PPG, in order to facilitate the successful accomplishment of the scientific goals. This Core will oversee the facilitation and organization of regular meetings of the Steering Committee (Project and Core Leaders). Agendas for these meetings will include review of progress on the overall goals of the PPG. The reviews will also include assessments of the logistics of all interactions between Projects and Cores in order to identify any potential bottlenecks in transfer of specimens, data, protocols, funds, or other items. The Project and Core Leaders will also review expenditures and allocations of resources for all Projects and Cores at least twice per year. Reports from the external and internal scientific advisory boards will be collated and reviewed by the Project and Core Leaders following each annual PPG annual review, which will occur during the annual retreat. The administrative core will oversee collection and collation of annual reports from all Project and Core Leaders and compiling it into the annual progress report to NIH. The PI of this PPG, along with the Program Administrator, will assure smooth operation of the scientific agenda of the program project. The Administrative Core will organize all aspects of the annual retreat, which will include Project and Core Leaders, Co-Leaders and their laboratory staffs, and Scientific Advisory Board Members. The Administrative Core will oversee the launch and maintenance of a Web page for this PPG will allow distribution of findings among the global community, while enabling sharing protocols, reagents as well as information among the projects in real time.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Program Projects (P01)
Project #
5P01CA163222-02
Application #
8736412
Study Section
Special Emphasis Panel (ZCA1)
Project Start
Project End
Budget Start
2014-03-01
Budget End
2015-02-28
Support Year
2
Fiscal Year
2014
Total Cost
Indirect Cost
Name
Massachusetts General Hospital
Department
Type
DUNS #
City
Boston
State
MA
Country
United States
Zip Code
02199
Eliades, Philip; Abraham, Brian J; Ji, Zhenyu et al. (2018) High MITF Expression Is Associated with Super-Enhancers and Suppressed by CDK7 Inhibition in Melanoma. J Invest Dermatol 138:1582-1590
Nguyen, Nhu T; Fisher, David E (2018) MITF and UV responses in skin: From pigmentation to addiction. Pigment Cell Melanoma Res :
Kapp, Friedrich G; Perlin, Julie R; Hagedorn, Elliott J et al. (2018) Protection from UV light is an evolutionarily conserved feature of the haematopoietic niche. Nature 558:445-448
Romano, Gabriele; Chen, Pei-Ling; Song, Ping et al. (2018) A Preexisting Rare PIK3CAE545K Subpopulation Confers Clinical Resistance to MEK plus CDK4/6 Inhibition in NRAS Melanoma and Is Dependent on S6K1 Signaling. Cancer Discov 8:556-567
Wein, Marc N; Foretz, Marc; Fisher, David E et al. (2018) Salt-Inducible Kinases: Physiology, Regulation by cAMP, and Therapeutic Potential. Trends Endocrinol Metab 29:723-735
Levy, Carmit; Golan, Tamar; Fisher, David E (2018) miRNA-211 stops the clock. Noncoding RNA Investig 2:
Reuben, Alexandre; Spencer, Christine N; Prieto, Peter A et al. (2017) Genomic and immune heterogeneity are associated with differential responses to therapy in melanoma. NPJ Genom Med 2:
Song, J S; London, W B; Hawryluk, E B et al. (2017) Risk of melanocytic nevi and nonmelanoma skin cancer in children after allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant 52:989-997
Dai, Jun; Choo, Min-Kyung; Park, Jin Mo et al. (2017) Topical ROR Inverse Agonists Suppress Inflammation in Mouse Models of Atopic Dermatitis and Acute Irritant Dermatitis. J Invest Dermatol 137:2523-2531
Alves, Cleidson P; Yokoyama, Satoru; Goedert, Lucas et al. (2017) MYO5A Gene Is a Target of MITF in Melanocytes. J Invest Dermatol 137:985-989

Showing the most recent 10 out of 89 publications